January 30
th
2012
Stanford Engineering,
European Entrepreneurship
& Innovation
Claus Crone FuglsangManaging DirectorNovozymes Inc.
2
A growing globalpopulation puts pressureon our natural resources.With bioinnovation in theform of, for example,industrial enzymes andmicroorganisms, industriescan rethink their processesand products, and producemore with less.
•
Business consists of two segments:Enzyme Business and BioBusiness
•
2011 sales: USD ~ 2 billion
•
2011 EBIT margin: 22.3%
•
More than 700 products used in 130countries in over 40 different industries
•
~ 7,000 granted and pending patents
•
+ 5,800 employees
•
Two share classes; A and B shares
•
A share capital and 11% of B shares
(25.5% of O/S; 70.1% of votes) held byNovo A/S, the management company of the Novo Nordisk Foundation
Novozymes
–
The World Leader in Bioinnovation
* A+B shares January, 2012
Founded 1941Listed 2000Ticker NZYM BExchange CopenhagenMarket Cap*~ 10 Billion USDEnzyme BusinessBioBusiness
HouseholdCareFood & BeveragesBioenergyFeed & other Tech.Micro-organismsBiopharma3
Search History:
Result 00 of 00
00 results for result for
p.
Claus Fuglsang - Novozymes - Stanford - Jan 30 2012
752
Reads
0
Readcasts
0
Embed Views
More From This User
Notes
Load more
